Curve Therapeutics, a Southampton, UK-based private biotechnology company, raised $40.5M in Series A funding.
The round was led by Pfizer Ventures with participation from Columbus Venture Partners and British Patient Capital, which joined founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital.
The company intends to use the funds to progress development of these assets rapidly towards clinical development and to expand the discovery platform beyond challenging and complex intracellular protein targets.
Led by CEO Simon Kerry, Curve Therapeutics is a biotechnology company providing an intracellular screening platform to enable the discovery of innovative therapeutics that address complex and challenging disease targets with the potential to transform the lives of patients.
Its Microcycle® platform enables the direct discovery of biologically active molecules against targets that have been difficult to address using conventional drug discovery methods. Curve has built a discovery pipeline of assets including a first-in-class dual-inhibitor of HIF-1 and HIF-2 that addresses survival mechanisms in more than half of solid tumours, and a first-in-class inhibitor of ATIC dimerization that targets an important vulnerability in multiple cancers.
FinSMEs
27/02/2024